Document Detail


Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation.
MedLine Citation:
PMID:  22168653     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
To the Editor: The investigators in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation study (ROCKET AF; ClinicalTrials.gov number, NCT00403767) (Sept. 8 issue)(1) reported that rivaroxaban was noninferior to warfarin in preventing stroke or systemic embolism. Furthermore, in the as-treated safety population, this primary end point was significantly less frequent in the group treated with rivaroxaban (P=0.01 for superiority). In an intention-to-treat analysis, however, there was no significant reduction in the primary end point (P=0.12 for superiority). Owing to the potential for confounding and . . .
Authors:
Scott Pearson; Richard Troughton; A Mark Richards
Related Documents :
25242773 - Ischemia time and liver transplantation, today.
11199683 - Restorative dentistry using a multidisciplinary approach.
186603 - Dysfunctional uterine bleeding.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The New England journal of medicine     Volume:  365     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2333-5     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation.
Next Document:  Cord colitis syndrome in cord-blood stem-cell transplantation.